Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Ocugen Inc (NQ: OCGN )

0.9862 -0.0938 (-8.69%)
Streaming Delayed Price Updated: 4:00 PM EST, Nov 8, 2024 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Ocugen Inc

< Previous 1 2
...
26 27 28 29 30 31 32 33 Next >
The Daily Biotech Pulse: Vir-GlaxoSmithKline COVID-19 Antibody Treatment Approved, Zosano Spikes On Long-Term Migraine Drug Data, Decision Day For Eton, 2 IPOs
Here's a roundup of top developments in the biotech space over the last 24 hours: Scaling The Peaks (Biotech Stocks Hitting 52-week Highs May 26) I-Mab (NASDAQ: IMAB)... 
Via Benzinga
Exposures COVID-19
OCGN Stock: The Big FDA News Lifting Ocugen Shares Today
OCGN stock is on the move today as biopharma Ocugen confirms its intent to submit an EUA for Covaxin in June 2021. 
Via InvestorPlace
Exposures COVID-19 Product Safety
24 Stocks Moving in Thursday's Pre-Market Session
Gainers Vertex Energy, Inc. (NASDAQ: VTNR) rose 82% to $3.24 in pre-market trading after the company announced plans to acquire a Alabama refinery and related logistics assets.... 
Via Benzinga
2 Reasons to Avoid Ocugen Stock -- and 1 Reason to Considering Buying It
The company has a path to success in the COVID-19 vaccine market, but it might be more of an uphill climb than some investors realize. 
Via The Motley Fool
Exposures COVID-19
Here's What Is Going On With Ocugen (OCGN) Stock
Shares of Ocugen Inc. (NASDAQ: OCGN), India-based Bharat Biotech’s U.S. partner for COVID-19 vaccine Covaxin, fell 3.7% in Wednesday’s regular trading session. What... 
Via Benzinga
Exposures COVID-19
FDA May Not Review New COVID-19 Vaccine Emergency Use Requests
The FDA, on Tuesday, said that it might decline to review and process new emergency use authorization (EUA) requests for COVID-19 vaccines for the rest of the pandemic... 
Via Benzinga
Exposures COVID-19 Product Safety
Bharat Biotech's US Partner Ocugen Submits Covaxin Master File for FDA Review
Ocugen Inc (NASDAQ: OCGN), India-based Bharat Biotech’s U.S. partner for COVID-19 vaccine Covaxin, has submitted a “Master File” to the FDA... 
Via Benzinga
Exposures COVID-19 Product Safety
Take Profits If You Own Ocugen Stock, but Now’s Not the Time to Buy
We don't know if the FDA will authorize emergency use for Covaxin. Therefore OCGN stock is a high risk investment. 
Via InvestorPlace
Exposures Product Safety
Ocugen vs. Inovio: Where Is the Smart Money Going?
They're both seeking share in the vaccine market. 
Via The Motley Fool
Exposures COVID-19
Ocugen Faces Long Odds Before Gaining From Its Covid-19 Support Role
Ocugen has skin in the Covid-19 vaccine game. But the company faces long odds on its partnership providing a long-term boost for OCGN stock. 
Via InvestorPlace
Exposures COVID-19
Stay On The Sidelines With Ocugen Stock
The small biopharmaceutical company has a promising Covid-19 vaccine, but the timing of its approval remains a question mark for OCGN stock. 
Via InvestorPlace
Exposures COVID-19
Ocugen Stock Is Left Behind As the U.S. Emerges From the Pandemic
There seems to be no need for Covaxin in the U.S. and there are no indications that the U.S. is considering approving it. Consequently, OCGN stock is worth shorting. 
Via InvestorPlace
Exposures COVID-19
Will Covaxin's Success Against COVID Variants Make Ocugen a Big Winner?
It's still really early. 
Via The Motley Fool
Exposures COVID-19
Ocugen or Vaxart: Which Will Take Investors Further?
These two high-flying biotechs are vying for the same market. 
Via The Motley Fool
Exposures COVID-19
Ocugen Has a Longer Road To Paying off Than People Think
Even after good news in recent days, OCGN stock is right back where it started. And that still doesn't create a buying opportunity. 
Via InvestorPlace
Can Ocugen Overcome This Major Hurdle?
It will determine whether the shares sink or skyrocket in the long term. 
Via The Motley Fool
Exposures COVID-19 Product Safety
Take a Look at Ocugen’s Work on Eye Diseases, Not Just Their Vaccine Partnership
With clinical data to support Ocugen's product candidate to treat multiple eye conditions, OCGN stock isn't just your typical "vaccine stock." 
Via InvestorPlace
Exposures COVID-19
Could Ocugen Be a Millionaire Maker Stock?
This coronavirus vaccine drugmaker has made investors rich in a very short period. Can it sustain its run? 
Via The Motley Fool
Exposures COVID-19
FDA To Hold AdCom Meeting For Expanding Use COVID-19 Vaccine In Children
The FDA’s Center for Biologics Evaluation and Research (CBER) will convene a virtual meeting of the Vaccines and Related Biological Products Advisory Committee on June 10... 
Via Benzinga
Exposures COVID-19 Product Safety
This Is Why Ocugen Crashed Despite Apparent Good News
Ocugen released a bunch of seemingly positive news in recent days. Yet OCGN stock tanked anyway. Here's why you should stay away from it. 
Via InvestorPlace
Exposures COVID-19
3 Investments That Turned $35,000 Into $1 Million (or More) in Just 6 Months
One security grew $35,000 into more than $9 million since early November. 
Via The Motley Fool
Topics Stocks
Exposures US Equities
Ocugen, Inc. (OCGN) Q1 2021 Earnings Call Transcript
OCGN earnings call for the period ending March 31, 2021. 
Via The Motley Fool
Topics Earnings
Exposures Financial
OCGN Stock: Why Red-Hot Ocugen Is Plunging Again Today
Ocugen (OCGN) stock taking a beating on Friday following the release of the biopharmaceutical company's earnings report for Q1 2021. 
Via InvestorPlace
Why Ocugen Stock Is Tanking Today
Investors didn't get what they wanted in the biotech's Q1 update. 
Via The Motley Fool
Ocugen Stock Has a Big Pullback Coming, and That Will Be Your Chance
OCGN Stock had a nice run in recent weeks but faces risks of a sharp pullback that could lead to paper losses for speculators. 
Via InvestorPlace
Exposures COVID-19
Ocugen Stock Is a Risky Proposition Despite Its High Valuation
OCGN stock soared on a deal to commercialize Bharat Biotech’s Covaxin in the U.S., but the rollout comes with a lot of challenges. 
Via InvestorPlace
12 Health Care Stocks Moving In Friday's Pre-Market Session
Gainers Assertio Holdings (NASDAQ:ASRT) shares moved upwards by 32.42% to $0.66 during Friday's pre-market session. The company's market cap stands at $114.5... 
Via Benzinga
Does Ocugen Have a Real Shot at the U.S. COVID Vaccine Market?
The biotech faces some big challenges. 
Via The Motley Fool
Exposures COVID-19
Better Vaccine Stock: Ocugen or Vaxart?
Here's how the biotechs compare on several key fronts. 
Via The Motley Fool
Exposures COVID-19
72 Biggest Movers From Yesterday
Gainers SemiLEDs Corporation (NASDAQ: LEDS) shares surged 85.8% to settle at $10.22 on above-average volume. Liquidity Services, Inc. (NASDAQ: LQDT) jumped 37.7% to settle at $25... 
Via Benzinga
< Previous 1 2
...
26 27 28 29 30 31 32 33 Next >
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.